A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
This is a phase II study that will investigate the efficacy, safety and tolerability of HRS-2261 in subjects with refractory chronic cough using a double blind, placebo controlled, randomized study design.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 304 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study of Efficacy and Safety of HRS-2261 in Refractory Chronic Cough
Estimated Study Start Date: March 30, 2023
Estimated Primary Completion Date: March 30, 2024
Estimated Study Completion Date: March 30, 2024
Arm:
- Experimental: HRS-2261 oral tablet
- Placebo Comparator: Matching placebo to HRS-2261
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 304 |
| Estimated Study start date | 30 March 2023 |
| Estimated Study Completion Date | 30 March 2024 |